NCT00887718

Positron Emission Tomography(PET) in Lymphoma Assessment

Positron Emission Tomography for Staging, and Treatment Assessment of Response in Lymphomas (the Pet-star Lymphoma Study)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 103 (actual)
• Sponsor: University Health Network, Toronto · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study examines the role of a diagnostic test called Positron Emission Tomography (PET) scanning in patients with malignant lymphoma. The primary goal of this study is to find out how well PET scanning can detect malignant (cancerous) lymphoma, and how often this extra information will result in a change of stage of disease, or will result in a change in treatment management plans of patients with lymphoma.

Detailed description

It is currently unknown whether modifying treatment based on FDG-PET results is appropriate. However, clinicians are increasingly using the FDG-PET result, where obtained, in deciding management. Consequently, it would be premature to mandate PET-based treatment modifications in this protocol. Patients will be treated with existing protocols at the discretion of their treating oncologists, based on available information. Oncologists will be surveyed as to whether FDG-PET scan results could have (or affect patient management, and the intervention will be recorded).

Conditions

• Hodgkin's Lymphoma
• Non Hodgkin's Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	PET Scan	18F-Fluorodeoxyglucose (FDG) injection

Timeline

• Start date: 2007-08-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2009-04-24
• Last updated: 2012-12-18

Locations

1 site across 1 country: Canada